Literature DB >> 24468786

An altered Mycobacterium tuberculosis metabolome induced by katG mutations resulting in isoniazid resistance.

Du Toit Loots1.   

Abstract

The most common form of drug resistance found in tuberculosis (TB)-positive clinical samples is monoresistance to isoniazid. Various genomics and proteomics studies to date have investigated this phenomenon; however, the exact mechanisms relating to how this occurs, as well as the implications of this on the TB-causing organisms function and structure, are only partly understood. Considering this, we followed a metabolomics research approach to identify potential new metabolic pathways and metabolite markers, which when interpreted in context would give a holistic explanation for many of the phenotypic characteristics associated with a katG mutation and the resulting isoniazid resistance in Mycobacterium tuberculosis. In order to achieve these objectives, gas chromatography-time of flight mass spectrometry (GCxGC-TOFMS)-generated metabolite profiles from two isoniazid-resistant strains were compared to a wild-type parent strain. Principal component analyses showed clear differentiation between the groups, and the metabolites best describing the separation between these groups were identified. It is clear from the data that due to a mutation in the katG gene encoding catalase, the isoniazid-resistant strains experience increased susceptibility to oxidative stress and have consequently adapted to this by upregulating the synthesis of a number of compounds involved in (i) increased uptake and use of alkanes and fatty acids as a source of carbon and energy and (ii) the synthesis of a number of compounds directly involved in reducing oxidative stress, including an ascorbic acid degradation pathway, which to date hasn't been proposed to exist in these organisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24468786      PMCID: PMC4023710          DOI: 10.1128/AAC.02344-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  The magic bullets and tuberculosis drug targets.

Authors:  Ying Zhang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

2.  Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using Genechips.

Authors:  Li M Fu; Thomas M Shinnick
Journal:  Tuberculosis (Edinb)       Date:  2006-08-02       Impact factor: 3.131

3.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 4.  Loss of oxyR in Mycobacterium tuberculosis.

Authors:  V Deretic; J Song; E Pagán-Ramos
Journal:  Trends Microbiol       Date:  1997-09       Impact factor: 17.079

5.  Mycobacterium tuberculosis possesses a functional enzyme for the synthesis of vitamin C, L-gulono-1,4-lactone dehydrogenase.

Authors:  Beata A Wolucka; David Communi
Journal:  FEBS J       Date:  2006-09-05       Impact factor: 5.542

Review 6.  Antituberculosis drugs: ten years of research.

Authors:  Yves L Janin
Journal:  Bioorg Med Chem       Date:  2007-01-19       Impact factor: 3.641

Review 7.  Stress responses in mycobacteria.

Authors:  Surbhi Gupta; Dipankar Chatterji
Journal:  IUBMB Life       Date:  2005-03       Impact factor: 3.885

Review 8.  The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

Authors:  A Somoskovi; L M Parsons; M Salfinger
Journal:  Respir Res       Date:  2001-04-05

Review 9.  Measuring the metabolome: current analytical technologies.

Authors:  Warwick B Dunn; Nigel J C Bailey; Helen E Johnson
Journal:  Analyst       Date:  2005-03-04       Impact factor: 4.616

10.  Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance.

Authors:  Karthik Raman; Nagasuma Chandra
Journal:  BMC Microbiol       Date:  2008-12-23       Impact factor: 3.605

View more
  11 in total

Review 1.  Metabolomics: Applications and Promise in Mycobacterial Disease.

Authors:  Mehdi Mirsaeidi; Mohammad Mehdi Banoei; Brent W Winston; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2015-09

Review 2.  Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.

Authors:  Robert S Jansen; Kyu Y Rhee
Journal:  Trends Pharmacol Sci       Date:  2017-02-03       Impact factor: 14.819

Review 3.  Mycobacterium tuberculosis metabolism.

Authors:  Digby F Warner
Journal:  Cold Spring Harb Perspect Med       Date:  2014-12-11       Impact factor: 6.915

4.  [Mass spectrometry-based identification of new serum biomarkers in patients with multidrug resistant pulmonary tuberculosis].

Authors:  Dongzi Lin; Wei Wang; Feng Qiu; Yumei Li; Xiaolin Yu; Bingyao Lin; Yinwen Chen; Chunyan Lei; Yan Ma; Jincheng Zeng; Jie Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

5.  Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study.

Authors:  Jennifer K Frediani; Dean P Jones; Nestan Tukvadze; Karan Uppal; Eka Sanikidze; Maia Kipiani; ViLinh T Tran; Gautam Hebbar; Douglas I Walker; Russell R Kempker; Shaheen S Kurani; Romain A Colas; Jesmond Dalli; Vin Tangpricha; Charles N Serhan; Henry M Blumberg; Thomas R Ziegler
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

6.  Breath can discriminate tuberculosis from other lower respiratory illness in children.

Authors:  Lili Kang; Lesley Workman; Heather J Zar; Jane E Hill; Carly A Bobak; Lindy Bateman; Mohammad S Khan; Margaretha Prins; Lloyd May; Flavio A Franchina; Cynthia Baard; Mark P Nicol
Journal:  Sci Rep       Date:  2021-02-01       Impact factor: 4.379

Review 7.  Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.

Authors:  Saad Alghamdi; Shaheed Ur Rehman; Nashwa Talaat Shesha; Hani Faidah; Muhammad Khurram; Sabi Ur Rehman
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

8.  Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

Authors:  Kirsten E Knoll; Zander Lindeque; Adetomiwa A Adeniji; Carel B Oosthuizen; Namrita Lall; Du Toit Loots
Journal:  Microorganisms       Date:  2021-05-28

Review 9.  Panomics for Precision Medicine.

Authors:  Charanjit Sandhu; Alia Qureshi; Andrew Emili
Journal:  Trends Mol Med       Date:  2017-12-05       Impact factor: 15.272

Review 10.  The use of functional genomics in conjunction with metabolomics for Mycobacterium tuberculosis research.

Authors:  Conrad C Swanepoel; Du Toit Loots
Journal:  Dis Markers       Date:  2014-03-18       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.